A LinkedIn post from Multiverse Computing highlights the development of epiGPTope, a generative AI model designed to support immunotherapy and vaccine research. The post explains that epiGPTope is built by fine-tuning ProtGPT2, a protein language model aimed at exploring new regions of protein sequence space.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, specializing the model on epitope data allows it to generate novel candidates intended to address the large combinatorial space of possible sequences in drug discovery. The work is presented as the result of a collaboration with CIC biomaGUNE, combining expertise in generative AI, biological datasets, and high-throughput experimental methods.
The post suggests that this approach could enable faster and more cost-effective discovery of epitope libraries, potentially supporting the development of next-generation vaccines and immunotherapies. For investors, this may indicate Multiverse Computing’s efforts to expand the application of its AI capabilities into biotech and drug discovery, potentially opening additional commercial avenues and partnerships in the life sciences sector.